IDEAYA Biosciences (IDYA) Income from Continuing Operations (2018 - 2026)
IDEAYA Biosciences (IDYA) reported Income from Continuing Operations of 232765000.0 for Q1 2026, down 149.92% on a YoY basis from 466280967.89 in Q1 2025, and down 146.43% sequentially from 94455000.0 in Q4 2025.
IDEAYA Biosciences (IDYA) Income from Continuing Operations (2018 - 2026) Analysis & Trends
IDEAYA Biosciences (IDYA) has 9 years of Income from Continuing Operations data on file, last reported at 232765000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 149.92% year-over-year to 232765000.0; the trailing twelve-month figure through Mar 2026 stood at 432489000.0 (up 19.34% YoY), and the FY2025 full-year result was 354263000.0, up 27.94% from the prior year.
- Income from Continuing Operations slipped to 232765000.0 in Q1 2026, from 94455000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 30153000.0 in Q3 2025 to a low of 232765000.0 in Q1 2026.
- A 5-year average of 74231352.94 and a median of 39174000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 379.35% in 2024 and jumped 122.45% in 2025, its largest moves.
- Tracing IDYA's Income from Continuing Operations over 5 years: stood at 25326000.0 in 2022, then plunged by 54.68% to 39174000.0 in 2023, then tumbled by 275.92% to 147262000.0 in 2024, then soared by 35.86% to 94455000.0 in 2025, then sank by 146.43% to 232765000.0 in 2026.
- Business Quant data shows IDYA's Income from Continuing Operations at 232765000.0 in Q1 2026, 94455000.0 in Q4 2025, and 30153000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | IDEAYA Biosciences | 3.21 Bn | 2.54 Bn | - | -232.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -232.77 Mn |
| Dec 31, 2025 | -94.46 Mn |
| Sep 30, 2025 | 30.15 Mn |
| Jun 30, 2025 | -135.42 Mn |
| Mar 31, 2025 | -93.14 Mn |
| Dec 31, 2024 | -147.26 Mn |
| Sep 30, 2024 | -134.32 Mn |
| Jun 30, 2024 | -161.44 Mn |
| Mar 31, 2024 | -53.54 Mn |
| Dec 31, 2023 | -39.17 Mn |
| Sep 30, 2023 | -33.87 Mn |
| Jun 30, 2023 | -33.68 Mn |
| Mar 31, 2023 | -26.28 Mn |
| Dec 31, 2022 | -25.33 Mn |
| Sep 30, 2022 | -18.18 Mn |
| Jun 30, 2022 | -37.92 Mn |
| Mar 31, 2022 | -25.31 Mn |
| Dec 31, 2021 | -20.88 Mn |
| Sep 30, 2021 | -11.83 Mn |
| Jun 30, 2021 | -11.07 Mn |